Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. Journal of the National Cancer Institute. 2013 Feb 6;105(3):175–201. [PMC free article: PMC3565628] [PubMed: 23297039]

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10–29. [PubMed: 22237781]

But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008 Mar 21;14(11):1652–1656. [PMC free article: PMC2695904] [PubMed: 18350595]

Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr;140(4):1182–1188.e1181. [PMC free article: PMC3073667] [PubMed: 21184757]

Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. Journal of Clinical Oncology. 2009 Mar 20;27(9):1485–1491. [PMC free article: PMC2668555] [PubMed: 19224838]

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; http://seer​.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site 2013. http://seer​.cancer.gov​/statfacts/html/livibd​.html#incidence-mortality.

Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology & Therapeutics. 2009 Jul;30(1):37–47. [PMC free article: PMC6871653] [PubMed: 19392863]

Bruix J, Sherman M., American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020–1022. [PMC free article: PMC3084991] [PubMed: 21374666]

Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Journal of Cancer. 2012;48(5):599–641. [PubMed: 22424278]

Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatology International. 2010;4(2):439–474. [PMC free article: PMC2900561] [PubMed: 20827404]

Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012 Mar 6;156(5):387–389. [PubMed: 22393134]

Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. New England Journal of Medicine. 2012 Nov 22;367(21):1998–2005. [PubMed: 23171096]

Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute. 2002 Jul 3;94(13):981–990. [PubMed: 12096083]

Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;(9):CD002799. [PMC free article: PMC6464874] [PubMed: 22972059]

Sherman M, Bruix J, Porayko M, Tran T. Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56(3):793–796. [PubMed: 22689409]

HSR&D. ESP Reports in Progress. http://www​.hsrd.research​.va.gov/publications​/esp/in_progress.cfm.

Treadwell J, Reston J, Singh S, Talati R, McPheeters M. Methods Research Report. Rockville, MD: Agency for Healthcare Research and Quality; Jun, 2011. A Framework for “Best Evidence” Approaches in Systematic Reviews. (Prepared by the ECRI Institute Evidence-based Practice Center under Contract No. HHSA 290-2007-10063-I.) AHRQ Publication No. 11-EHC046-EF. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.June. [PubMed: 21834173]

Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002 Mar;35(3):519–524. [PubMed: 11870363]

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine. 1996 Mar 14;334(11):693–699. [PubMed: 8594428]

Part 2, Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors; Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2008;Version 5.10. The Cochrane Collaboration; 2008. [June 12, 2013]. Updated March 2011. www​.cochrane-handbook.org.

Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology. 2011 Apr;64(4):380–382. [PubMed: 21185693]

Viswanathan M, Mohammed A, Berkman N, et al. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. [PubMed: 22764383]

Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):1–173. [PubMed: 14499048]

Patient-Centered Outcomes Research Institute. PCORI Methodology Standards. 2012 December 14

The AGREE Next Steps Consortium. Appraisal of Guidelines for Research & Evaluation II (AGREE II) Instrument. May, 2009. www​.agreetrust.org.

Silva MA, Hegab B, Hyde C, Guo B, Buckels JAC, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008 Nov;57(11):1592–1596. [PubMed: 18669577]

Asiyanbola B, Chang D, Gleisner AL, et al. Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg. 2008 May;12(5):842–851. [PubMed: 18266046]

Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul;130(7):417–422. [PubMed: 15042359]

Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10(4):204–209. [PubMed: 14738659]

Wang JH, Chang KC, Kee KM, et al. Hepatocellular Carcinoma Surveillance at 4- vs. 12-Month Intervals for Patients With Chronic Viral Hepatitis: A Randomized Study in Community. Am J Gastroenterol. 2013 Jan 15 [PubMed: 23318478]

Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011 Dec;54(6):1987–1997. [PubMed: 22144108]

Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001 Feb;48(2):251–259. [PMC free article: PMC1728189] [PubMed: 11156649]

Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002 Mar 10;98(2):257–261. [PubMed: 11857416]

Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007 Sep;41(8):777–782. [PubMed: 17700427]

El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011 Jul;60(7):992–997. [PubMed: 21257990]

Giannini E, Arzani L, Borro P, et al. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Hepatogastroenterology. 2000 Sep-Oct;47(35):1395–1398. [PubMed: 11100360]

Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005 Jun;20(6):873–881. [PubMed: 15946134]

Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010 Mar;46(4):744–751. [PubMed: 20060710]

Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol. 2007 Apr;5(4):508–512. [PubMed: 17382601]

Pascual S, Irurzun J, Zapater P, et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. Liver International. 2008;28(5):682–689. [PubMed: 18433394]

Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006 Jun;26(5):543–551. [PubMed: 16761998]

Taura N, Hamasaki K, Nakao K, et al. Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospital-based study. Oncol Rep. 2005 Oct;14(4):999–1003. [PubMed: 16142364]

Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010 Mar;55(3):826–835. [PubMed: 19960258]

Trevisani F, De NS, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002 Mar;97(3):734–744. [PubMed: 11922571]

Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004 Aug;99(8):1470–1476. [PubMed: 15307862]

Wong GLH, Wong VWS, Tan GM, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver International. 2008;28(1):79–87. [PubMed: 17900247]

Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J. 2004 Sep-Oct;10(5):317–325. [PubMed: 15530261]

Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology. The essentials. 2nd ed. Baltimore: Williams and Wilkins; 1988.

Ahn DW, Shim JH, Yoon JH, et al. Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma. Korean J Hepatol. 2011 Jun;17(2):106–112. [PMC free article: PMC3304641] [PubMed: 21757981]

Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Comparative Effectiveness Review No. 69. Rockville, MD: Agency for Healthcare Research and Quality; Nov, 2012. Screening for Hepatitis C Virus Infection in Adults. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.) AHRQ Publication No. 12(13)-EHC090-EF. www​.effectivehealthcare​.ahrq.gov/reports/final.cfm. [PubMed: 23304739]

Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Annals of Internal Medicine. 2011;154(2):85–93. [PubMed: 21242365]

El-Serag HB, Alsarraj A, Richardson P, et al. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Digestive Diseases & Sciences. 2013 Nov;58(11):3117–3126. [PMC free article: PMC3858077] [PubMed: 23868438]

Groupe d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med. 1995 May 11;332(19):1256–1261. [PubMed: 7708069]

Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990 Sep;11(2):181–184. [PubMed: 2174933]

Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164–1171. [PubMed: 11981766]

Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734–1739. [PubMed: 12049862]

Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol. 2004 Mar;11(3):298–303. [PubMed: 14993025]

Tong MJ, Chavalitdhamrong D, Lu DS, et al. Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA. J Clin Gastroenterol. 2010 Mar;44(3):e63–70. [PubMed: 19745756]

Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2009 Jun;15(6):574–580. [PubMed: 19479800]

Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013 Feb;58(2):287–296. [PubMed: 23099188]

Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008 May;134(5):1342–1351. [PubMed: 18471511]

Lee SS, Shin HS, Kim HJ, et al. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol. 2012 Mar;18(1):48–55. [PMC free article: PMC3326996] [PubMed: 22511903]

Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008 Jan;47(1):82–89. [PubMed: 18008357]

DuBay DA, Sandroussi C, Kachura JR, et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011 Jan;13(1):24–32. [PMC free article: PMC3019538] [PubMed: 21159100]

Imamura J, Tateishi R, Shiina S, et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol. 2008 Dec;103(12):3057–3062. [PubMed: 19086957]

Chen WT, Fernandes ML, Lin CC, Lin SM. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program. Journal of Surgical Oncology. 2011;103(2):133–139. [PubMed: 21259246]

Cottone M, Virdone R, Fusco G, et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology. 1989 Jun;96(6):1566–1571. [PubMed: 2469617]

Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986 Feb;90(2):289–298. [PubMed: 2416627]

Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. 1985 Aug;89(2):259–266. [PubMed: 2408960]

Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992 Jul;16(1):132–137. [PubMed: 1352268]

Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999 Jan;29(1):62–67. [PubMed: 9862851]

Chou R. Evidence-based Practice Center Systematic Review Protocol. AHRQ Effective Health Care Program; Imaging Techniques for the Surveillance, Diagnosis, and Staging of Hepatocellular Carcinoma. http:​//effectivehealthcare​.ahrq.gov/ehc/products​/479/1600/Liver-cancer-protocol-130724.pdf.

Rahman A, Assifi MM, Pedroso FE, et al. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg. 2012 Oct;16(10):1897–1909. [PubMed: 22836922]

Kanwal F, Befeler A, Chari RS, et al. Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network. Alimentary Pharmacology & Therapeutics. 2012 Aug;36(3):257–265. [PubMed: 22670798]

Schlansky B, Chen Y, Austin D, Naugler WE. Wait list time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study in the UNOS registry. Hepatology. 2013;58(4 (Suppl) AASLD Abstracts):208A.

Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010 Apr;51(4):1274–1283. [PubMed: 20112254]

Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Annals of Oncology. 1997 Feb;8(2):117–136. [PubMed: 9093719]

Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):53S–70S. [PMC free article: PMC3278053] [PubMed: 22315256]

Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technology Assessment (Winchester, England). 2003;7(41):1–90. [PubMed: 14670218]

Farinati F, Giacomin A, Vanin V, et al. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. Eur J Gastroenterol Hepatol. 2012 Feb;24(2):195–202. [PubMed: 22108511]

Mahady SE, Charlton B, Fitzgerald P, et al. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol. 2010 Jul;25(7):1299–1305. [PubMed: 20594260]

Eltawil KM, Berry R, Abdolell M, Molinari M. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. HPB (Oxford). 2012 May;14(5):341–350. [PMC free article: PMC3384854] [PubMed: 22487072]